Adnexus Biotechnologies is a biotechnology company, with a specialized focus on diagnosing, preventing, and treating infectious diseases. Our approach is multi-faceted, leveraging three complementary platforms that work in synergy to generate our clinical products. Each platform is a testament to our commitment to innovation and excellence, contributing to a robust pipeline of solutions that are set to redefine healthcare. At Adnexus, we’re not just developing drugs – we’re shaping the future of medicine.
HIV CAPSID INHIBITOR
has a wholly-owned AI platform that drives:
Early Drug Discovery & Development and
Builds Intellectual Property Portfolio
that produces multiple antibodies against infectious diseases
Anti-HIV monoclonal antibodies (mAbs).-Monoclonal antibodies directed against the HIV virus.
Anti-SARS-CoV-2 monoclonal antibodies (mAbs)-Monoclonal antibodies directed against the Coronavirus (all variants).
For more information on our services and research projects, please click here to submit an enquiry.